AI assistant
Citius Pharmaceuticals, Inc. — Director's Dealing 2021
Oct 13, 2021
34965_dirs_2021-10-13_d929e69c-2c24-4166-8e40-98580af422af.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Citius Pharmaceuticals, Inc. (CTXR)
CIK: 0001506251
Period of Report: 2021-10-11
Reporting Person: Czuczman Myron (Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-10-11 | Stock Option (Right to Purchase Common Stock) | $2.04 | A | 300000 | Acquired | 2031-10-11 | Common Stock (300000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Purchase Common Stock) | $1.19 | 2030-07-14 | Common Stock (500000) | 500000 | Direct |
Footnotes
F1: The options were granted on October 11, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F2: One-third of the shares of the Company's common stock underlying the grant vest on the one-year anniversary of the Vesting Commencement Date, July 14, 2020, with the remainder vesting in 24 equal monthly installments thereafter, provided that the Optionee provides Continuous Service to the Company on each such vesting date.